Scynexis (SCYX) Net Equity Issued and Repurchased (2016 - 2025)
Scynexis' (SCYX) quarterly Net Equity Issued and Repurchased came in at $1000.0 in Q4 2025, up 125.0% quarter-over-quarter from -$4000.0 in Q3 2023.
Analysis
Scynexis (SCYX) Net Equity Issued and Repurchased (2016 - 2025) Analysis & Trends
Scynexis (SCYX) has reported Net Equity Issued and Repurchased for 9 consecutive years, with $1000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Dec 2025 stood at -$3000.0 (changed N/A YoY), and the FY2025 full-year result was $5000.0, changed N/A from the prior year.
- Net Equity Issued and Repurchased climbed to $1000.0 in Q4 2025 per SCYX's latest filing, from -$4000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $30.5 million in Q4 2021 and bottomed at -$4000.0 in Q3 2023.
- Historically, Net Equity Issued and Repurchased has averaged $4.5 million across 4 years, with a median of $450000.0 in 2021.
- The sharpest annual moves came in 2021 and 2023: Net Equity Issued and Repurchased surged 333.33% in 2021, then plunged 104.0% in 2023.
- Over 4 years, Net Equity Issued and Repurchased stood at $30.5 million in 2021, then tumbled by 99.67% to $100000.0 in 2022, then slumped by 104.0% to -$4000.0 in 2023, then surged by 125.0% to $1000.0 in 2025.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $1000.0, -$4000.0, and $4000.0 for Q4 2025, Q3 2023, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 9.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 49.20 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 2.16 Mn |
| Dec 31, 2021 | 30.53 Mn |
| Sep 30, 2021 | 2.60 Mn |
| Jun 30, 2021 | 800,000.00 |
| Dec 31, 2020 | 85.85 Mn |
| Sep 30, 2020 | 600,000.00 |
| Jun 30, 2020 | 2.54 Mn |
| Mar 31, 2020 | 214,000.00 |
| Dec 31, 2019 | 36.27 Mn |
| Sep 30, 2019 | 3.31 Mn |
| Jun 30, 2019 | 4.17 Mn |
| Mar 31, 2019 | 2.59 Mn |
| Dec 31, 2018 | 958,000.00 |
| Sep 30, 2018 | 507,000.00 |
| Mar 31, 2018 | 30.19 Mn |
| Dec 31, 2017 | 1.36 Mn |